C-Path’s TRxA launches 2024 grants to boost next-gen therapeutics

Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe.

Edetate disodium-based chelation ineffective for heart attack patients with diabetes

People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium-based chelation, a therapy that draws lead and other toxic

April 8, 2024

Pfizer cuts 210 North Carolina workers after it officially discontinues failed Duchenne gene therapy

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 30, 2024

Frontotemporal Dementia (FTD) drugs in development, 2024

GlobalData tracks 119 drugs in development for Frontotemporal Dementia (FTD) by 92 companies/universities/institutes. The top development phase for Frontotemporal Dementia (FTD) is preclinical, with 66

August 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.